|
||
Thyrozol Uses |
||
Drug treatment of hyperthyroidism, especially in slight or absent thyroid enlargement (goiter) as well as in younger patients.
Preparation for surgery in all forms of hyperthyroidism.
Preparation of patients with hyperthyroidism for radioiodine treatment.
Intermittent treatment after radioiodine therapy.
In exceptional cases, for long-term therapy of hyperthyroidism where definite therapeutic measures are not applicable due to the patient's general condition, due to personal reasons or because they are rejected, and where Thyrozol (at the lowest possible dose) is well tolerated.
Prophylactic treatment in patients with a history of hyperthyroidism and autonomous adenomas where iodine exposure is indispensible (eg, examination with iodine-containing contrast media).
Each film-coated tablet contains Thiamazole 5 mg and 10 mg, respectively. It also contains the following excipients: Lactose monohydrate, cornstarch, cellulose powder, talc, methylhydroxypropyl cellulose, magnesium stearate, poly(O-carboxymethyl) starch sodium salt, silicon dioxide, macrogol 400, dimethicone 100, colourings E171 and E172.
General Dosage Recommendations: Adults: Inhibition of thyroid hormone production can usually be achieved with daily dose of Thyrozol 25-40 mg.
Mild Cases: Initial Dose: Thyrozol 20 mg may be considered.
Severe Cases: Initial Dose: Thyrozol 40 mg may be required.
For maintenance therapy, one of the following treatment options is recommended. Daily maintenance dose of Thyrozol 5-20 mg in combination with levothryoxine, in order to avoid hypothyroidism; monotherapy with daily doses of Thyrozol 2.5 mg and 10 mg. Iodine-induced hyperthyroidism may possibly require higher dosages.
Children: Initial dose depending on the severity of the disease: 0.3-0.5 mg/kg body weight/day.
Maintenance Dose: 0.2-0.3 mg/kg body weight/day.
Conservative Treatment of Hyperthyroidism: In conservative treatment of hyperthyroidism, therapy is usually continued over a period of 6 months to 2 years (1 year on average). Statistically, the probability of remission increases with the duration of therapy.
In cases, where remission of the disease cannot be achieved and definite therapeutic measures do not apply or are rejected, Thyrozol may be used as long-term antithyroid therapy in as low a dosage as possible without addition or in combination with a low dose of levothyroxine.
Patients with large goiters and constriction of the trachea should, if at all, only undergo short-term treatment with Thyrozol, since long-term administration can result in goiter growth. It may be necessary to monitor therapy particularly thoroughly [thyroid stimulating hormone (TSH) level, tracheal lumen]. The treatment is preferably combined with thyroid hormones.
Preoperative Therapy: Temporary pre-treatment, (≥3-4 weeks, if individually needed), may serve to achieve a euthyroid metabolic condition thus reducing surgery-related risks.
Surgery should be performed as soon as the patient is euthyroid, as otherwise, supplementary thyroid hormones must be administered. Treatment may be terminated the day before the surgery.
The Thyrozol-induced increased brittleness and bleeding tendency of thyroid tissues may be compensated by additional preoperative adminstration of high-dose iodine during the 10 days preceding surgery (Plummer's iodine therapy).
Treatment Before Radioiodine Therapy: Achievement of euthyroid metabolism, before initiation of radioiodine therapy is important particulary in severe hyperthyroidism, as post-therapeutic thyrotoxic crisis has occured in individual cases after such therapy without pre-treatment.
Note: Thiourea derivatives may reduce the radiosensitivity of the thyroid tissue. In scheduled radioiodine therapy of autonomous adenoma, activation of paranodular tissue by means of pre-treatment must be prevented.
Intermittent Antithyroid Therapy After Treatment with Radioiodine: The duration and dose if treatment must be defined individually depending on the severity of the clinical picture and the estimated period until radioiodine therapy starts to be effective (approximately 4-6 months).
Long-Term Antithyroid Therapy in Cases Where Remission of the Disease Cannot be Achieved and Definite Therapeutic Measures do not Apply or are Rejected: Thyrozol in as low a dose as possible (2.5-10 mg/day) without additional or together with a small amount of thyroid hormone.
Prophylactic Treatment in Patients with a History of Hyperthyroidism and Autonomous in whom Iodine Exposure is Indispensable: In general, daily doses of Thyrozol 10-20 mg and/or perchlorate 1 g are administered for approximately 10 days (eg, for renally excreted contrast media). The duration of treatment depends on the period of time for which the iodine-containing substance is retained in the body.
Hepatic Impairment: In patients with hepatic impairment, the plasma clearance of Thyrozol is reduced. Therefore, the dose should be kept as low as possible and patients should be closely monitored.
Renal Impairment: Due to the lack of pharmacokinetic data for Thyrozol in patients with renal impairment, careful individual dose adjustment under close monitoring is recommended. The dose should be as low as possible.
Elderly: Although the accumulation is expected in elderly patients, careful individual dose adjustment with close monitoring is recommended.
Administration: Thyrozol tablets are to be swallowed whole with sufficient liquid after meals.
During high-dose initial therapy of hyperthyroidism, the above stated single doses can be subdivided and taken at regular intervals over the day.
The maintenance dose can be taken all at once in the morning during or after breakfast.
Iodine deficiency increases the response of the thyroid to Thyrozol, whereas iodine excess lowers the response. Further direct interactions with other medicinal products are not known. However, it should be taken into account that the metabolism and elimination of other medicinal products can be accelerated in hyperthyroidism. It normalize in correlation with increasing normalization of the thyroid function. The dosage must be adjusted where necessary.
Furthermore, there are signs indicating that improvement of hyperthyroidism may normalize the enhance activity of anticoagulants in hyperthyroid patients.
The assessment of adverse reactions is based on the following frequency grouping: Very common (≥1/10), frequently (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10,000, <1/1000), very rare (<1/10,000).
Blood and Lymphatic System Disorders: Uncommon: Agranulocytosis occur about 0.3-0.6% of cases. It can still manifest weeks or months after the start of therapy and necessitate discontinuation of the medication. In most cases, it recedes spontaneously. Very Rare: Thrombocytopenia, pancytopenia, generalized lymphadenopathy.
Endocrine Disorders: Very Rare: Insulin autoimmune syndrome (with pronounced decline in blood glucose level).
Nervous System Disorders: Rare: Taste disturbances (dysgeusia, ageusia) occur rarely; they can recede after discontinuation of therapy. A return to normal can take several weeks however. Very Rare: Neuritis, polyneuropathia.
Gastointestinal Disorders: Very Rare: Acute swelling of salivary gland.
Hepatobiliary Disorders: Very Rare: Individual cases of cholestatic jaundice or toxic hepatitis has been described. The symptoms generally recede after discontinuation of Thyrozol. Clinically inapparent signs of cholestasis during treatment have to be differentiated from disturbances caused by hyperthyroidism, eg, an increase in γ-glutamyl transferase (GGT) and alkaline phosphatase or its bone-specific isoenzyme.
Skin and Subcutaneous Disorders: Very Common: Allergic skin reaction of varying degress (pruritus, rash, urticaria). They mostly take a mild course and frequently recede during continued therapy. Very Rare: Severe forms of allergic skin reactions including generalized dermatitis. Alopecia. Drug-induced lupus erythematosus.
Muscoskeletal and Connective Tissue Disorders: Common: Arthralgia may develop gradually and occur even after several months of therapy.
General Disorders and Administration Site Conditions: Rare: Fever.
Hypersensitivity to Thyrozol, other thionamide derivatives or any of the excipients of Thyrozol. Patients with moderate to severe blood count disturbances (granulocytopenia); preexisting cholestasis not caused by hyperthyroidism; previous damage to bone marrow after treatment with carbimazole or Thyrozol.
Combination therapy with Thyrozol and thyroid hormones is contraindicated during pregnancy.
Thiamazole in Bulgaria, Chile, China, Czech Republic, Estonia, France, Germany, Indonesia, Latvia, Lithuania, Peru, Poland, Romania, Russian Federation, Serbia, Singapore, Tunisia, Vietnam.
Unit description / dosage (Manufacturer) | Price, USD |
Tablet, Film-Coated; Oral; Methimazole 5 mg | |
Tablet, Film-Coated; Oral; Methimazole 10 mg | |
Thyrozol 5 mg x 100's | $ 12.94 |
Thyrozol 10 mg x 100's | $ 18.28 |
Thyrozol 5 mg x 10 Blister x 10 Tablet | |
Thyrozol 10 mg x 10 Blister x 10 Tablet | |
Thyrozol 5 mg x 10 x 10's | |
Thyrozol 10 mg x 10 x 10's | |
Thyrozol 20 mg x 3 x 10's | |
Thyrozol FC tab 10 mg 10 x 10's (Merck) | |
Thyrozol FC tab 5 mg 10 x 10's (Merck) | |
List of Thyrozol substitutes (brand and generic names): | |
Thiafeline 5 mg voor katten (Netherlands) | |
Thiafeline 5mg (France, Switzerland) | |
Thiafeline chats (Belgium) | |
Thiafeline vet (Estonia, Iceland, Poland) | |
Thiamatab (Germany) | |
Thiamatab 2.5mg (Switzerland) | |
Thiamatab 5mg (Switzerland) | |
Thiamazol | |
Thiamazol 1A Farma (Denmark) | |
Thiamazol Aristo (Germany) | |
Thiamazol Henning (Germany) | |
Injectable; Injection; Methimazole 40 mg / ml | |
Tablet, Film-Coated; Oral; Methimazole 5 mg | |
Tablet, Film-Coated; Oral; Methimazole 20 mg | |
Thiamazol Hexal (Germany) | |
Thiamazol Lindopharm (Germany) | |
Thiamazol Sandoz (Austria) | |
Thiamazol Sandoz 20 mg (Austria) | |
Thiamazole (Bulgaria, Chile, China, Czech Republic, Estonia, France, Germany, Indonesia, Latvia, Lithuania, Peru, Poland, Romania, Russian Federation, Serbia, Singapore, Tunisia, Vietnam) | |
Tablet; Oral; Methimazole 5 mg (Merck) | |
Thiamazole Merck (Lithuania) | |
Thiamazole Uni-Pharma (Denmark, Sweden) | |
Thimazol (Taiwan) | |
Thimazol 5 mg x 500's | |
Thimazole | |
Thycapsol | |
Thycapzol (Denmark) | |
Tablet; Oral; Methimazole 5 mg (Sandoz) | |
Thyrazol (Philippines) | |
Thyrazol 5 mg x 100's | $ 13.33 |
Thyromazol (Turkey) | |
Thyrozol 10mg (Germany) | |
Thyrozol 20mg (Germany) | |
Thyrozol 5mg (Germany) | |
Tiamazol (Peru) | |
Tiarotec (Mexico) | |
Tiastat (Serbia) | |
Timazol (Thailand) | |
Timazol 5 mg x 50 x 10's (Sriprasit Pharma) | |
Timazol tab 5 mg 50 x 10's (Sriprasit Pharma) | |
Tirodril (Spain) | |
Tirozol (Georgia) | |
Tirozol 5 / 10 | |
Tirozol 5/10 (Chile) | |
Tizorol (Mexico) | |
Tablet; Oral; Methimazole 5 mg (Rudefsa) | |
Tablet; Oral; Methimazole 20 mg (Rudefsa) | |
Unimazole (Greece) | |
See 183 substitutes for Thyrozol |
Users | % | ||
---|---|---|---|
Expensive | 1 | 100.0% |
Users | % | ||
---|---|---|---|
1 month | 3 | 42.9% | |
> 3 month | 3 | 42.9% | |
1 day | 1 | 14.3% |
Users | % | ||
---|---|---|---|
30-45 | 9 | 60.0% | |
16-29 | 4 | 26.7% | |
46-60 | 2 | 13.3% |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|